Gold bars to be exempt from tariffs, White House clarifies
SCOTTSDALE, Ariz. - Journey Medical Corporation (NASDAQ:DERM), a specialty pharmaceutical company with a market capitalization of $148 million and impressive gross margins of 65%, announced that data from two Phase 3 clinical trials shows its rosacea treatment Emrosi demonstrated consistent efficacy regardless of patient body weight. According to InvestingPro data, the company’s stock has surged over 35% in the past six months, reflecting growing investor confidence in its product pipeline.
The analysis, which will be presented at the Society of Dermatology Physician Associates 2025 Summer Conference on June 25-29 in Washington, DC, evaluated the drug’s performance in treating moderate-to-severe papulopustular rosacea in adults. With annual revenue of $56.24 million and its next earnings report scheduled for August 12, 2025, investors are closely monitoring the company’s progress in commercializing Emrosi.
According to the company’s statement, the data demonstrated that Emrosi, which received FDA approval in November 2024, can be prescribed without adjusting dosage based on a patient’s weight.
"This is an important attribute, as it avoids the potential for errors in dose calculations," said Julie Harper, MD, past president of the American Acne & Rosacea Society.
The trials, known as MVOR-1 and MVOR-2, involved 653 participants randomized to receive Emrosi, doxycycline 40 mg, or placebo once daily for 16 weeks. The analysis divided participants into groups based on whether they were above or below the median body weight of approximately 83 kg.
Results showed Emrosi was superior to both placebo and doxycycline on the primary endpoints across both weight categories. The most common adverse reaction reported was dyspepsia, occurring in at least 1% of subjects.
Emrosi is the lowest FDA-approved oral dose of minocycline that does not require weight-based dosing adjustments, according to the company’s press release. The prescription medication is currently available through specialty pharmacy chains.
Rosacea affects an estimated 16 million Americans and up to 415 million people worldwide, primarily adults between 30 and 50 years of age. While Journey Medical is currently not profitable, the substantial market opportunity has attracted investor attention. For deeper insights into Journey Medical’s financial health and growth prospects, including exclusive ProTips and comprehensive analysis, visit InvestingPro, where you’ll find detailed research reports covering 1,400+ top stocks.
In other recent news, Journey Medical Corp reported its first-quarter 2025 earnings, revealing that the company exceeded revenue expectations with $13.1 million, surpassing the forecast of $12.06 million. Despite the revenue beat, the company posted a net loss of $0.18 per share, missing the anticipated loss of $0.10 per share. The company also reported a significant improvement in its gross margin, which increased to 64% from 54% the previous year. A noteworthy development was the successful launch of AMROCI, a new treatment for rosacea, which contributed $2 million to the quarterly revenue. Analysts from firms like AGP and B. Riley Securities expressed interest in the initial market reception of AMROCI, with Journey Medical noting positive prescription trends. The company also announced that approximately 30% of commercially insured lives now have access to AMROCI, a significant increase from 20% earlier this year. Journey Medical aims to achieve EBITDA positivity later in 2025, driven by growth in new and legacy products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.